200 related articles for article (PubMed ID: 24583226)
1. TATI as a biomarker.
Itkonen O; Stenman UH
Clin Chim Acta; 2014 Apr; 431():260-9. PubMed ID: 24583226
[TBL] [Abstract][Full Text] [Related]
2. Emerging Roles of SPINK1 in Cancer.
Räsänen K; Itkonen O; Koistinen H; Stenman UH
Clin Chem; 2016 Mar; 62(3):449-57. PubMed ID: 26656134
[TBL] [Abstract][Full Text] [Related]
3. Biochemistry and clinical role of trypsinogens and pancreatic secretory trypsin inhibitor.
Paju A; Stenman UH
Crit Rev Clin Lab Sci; 2006; 43(2):103-42. PubMed ID: 16517420
[TBL] [Abstract][Full Text] [Related]
4. Biology and function of tumor-associated trypsin inhibitor, TATI.
Stenman UH; Koivunen E; Itkonen O
Scand J Clin Lab Invest Suppl; 1991; 207():5-9. PubMed ID: 1780691
[TBL] [Abstract][Full Text] [Related]
5. [Determination of tumor-associated trypsin inhibitor (TATI) in subjects with gastrointestinal diseases. Preliminary data].
Piantino P; Mosso R; Polloni R; Cerchier A; Gennaretti G; Daziano E
Minerva Med; 1989 Mar; 80(3):199-203. PubMed ID: 2717042
[TBL] [Abstract][Full Text] [Related]
6. Tumour-associated trypsin inhibitor and tumour-associated trypsin.
Stenman UH
Scand J Clin Lab Invest Suppl; 1990; 201():93-101. PubMed ID: 2244188
[TBL] [Abstract][Full Text] [Related]
7. Tumour-associated trypsin inhibitor TATI is a prognostic marker in colorectal cancer.
Koskensalo S; Hagström J; Louhimo J; Stenman UH; Haglund C
Oncology; 2012; 82(4):234-41. PubMed ID: 22508321
[TBL] [Abstract][Full Text] [Related]
8. Tumor-associated trypsin inhibitor in normal and malignant renal tissue and in serum of renal-cell carcinoma patients.
Lukkonen A; Lintula S; von Boguslawski K; Carpén O; Ljungberg B; Landberg G; Stenman UH
Int J Cancer; 1999 Nov; 83(4):486-90. PubMed ID: 10508484
[TBL] [Abstract][Full Text] [Related]
9. Serine protease inhibitor Kazal type 1 mutations and pancreatitis.
Schneider A
Gastroenterol Clin North Am; 2004 Dec; 33(4):789-806. PubMed ID: 15528018
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of tumor-associated trypsin inhibitor (SPINK1/TATI) in hepatitis C-associated hepatocellular carcinoma: potential implications for viral hepatocarcinogenesis.
Hass HG; Jobst J; Vogel U; Scheurlen M; Nehls O
Oncol Res Treat; 2014; 37(12):732-8. PubMed ID: 25531719
[TBL] [Abstract][Full Text] [Related]
11. Assessment of tumor-associated trypsin inhibitor (TATI) as a marker of renal function.
Tramonti G; Ferdeghini M; Annichiarico C; Donadio C; Norpoth M; Mantuano E; Bianchi C
J Nephrol; 2003; 16(5):663-72. PubMed ID: 14733412
[TBL] [Abstract][Full Text] [Related]
12. Autocrine induction of invasion and metastasis by tumor-associated trypsin inhibitor in human colon cancer cells.
Gouyer V; Fontaine D; Dumont P; de Wever O; Fontayne-Devaud H; Leteurtre E; Truant S; Delacour D; Drobecq H; Kerckaert JP; de Launoit Y; Bracke M; Gespach C; Desseyn JL; Huet G
Oncogene; 2008 Jul; 27(29):4024-33. PubMed ID: 18317448
[TBL] [Abstract][Full Text] [Related]
13. Susceptibility to pancreatitis related to PSTI/SPINK1 expression.
Liddle RA
Gastroenterol Clin North Am; 2004 Dec; 33(4):807-16. PubMed ID: 15528019
[TBL] [Abstract][Full Text] [Related]
14. Tumor-associated trypsin inhibitor (TATI) and tumor-associated trypsin-2 (TAT-2) predict outcomes in gastric cancer.
Kasurinen A; Laitinen A; Kokkola A; Stenman UH; Böckelman C; Haglund C
Acta Oncol; 2020 Jun; 59(6):681-688. PubMed ID: 32124669
[No Abstract] [Full Text] [Related]
15. Roles of serine protease inhibitor Kazal type 1 (SPINK1) in pancreatic diseases.
Ohmuraya M; Yamamura K
Exp Anim; 2011; 60(5):433-44. PubMed ID: 22041280
[TBL] [Abstract][Full Text] [Related]
16. An immunocapture-LC-MS-based assay for serum SPINK1 allows simultaneous quantification and detection of SPINK1 variants.
Ravela S; Valmu L; Domanskyy M; Koistinen H; Kylänpää L; Lindström O; Stenman J; Hämäläinen E; Stenman UH; Itkonen O
Anal Bioanal Chem; 2018 Feb; 410(6):1679-1688. PubMed ID: 29318362
[TBL] [Abstract][Full Text] [Related]
17. Tumor-associated trypsin inhibitor in patients with chronic pancreatic diseases.
Plebani M; Basso D; Fabris C; Meggiato T; Del Favero G; Panozzo MP; Fogar P; Faggian D; Angonese C; Burlina A
Klin Wochenschr; 1989 Oct; 67(20):1029-32. PubMed ID: 2586008
[TBL] [Abstract][Full Text] [Related]
18. Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells.
Paju A; Hotakainen K; Cao Y; Laurila T; Gadaleanu V; Hemminki A; Stenman UH; Bjartell A
Eur Urol; 2007 Dec; 52(6):1670-9. PubMed ID: 17306443
[TBL] [Abstract][Full Text] [Related]
19. TATI (tumor associated trypsin inhibitor) and cancer antigen 125 (CA 125) in patients with early-stage endometrial cancer.
Peters-Engl C; Buxbaum P; Ogris E; Sevelda P; Medl M
Anticancer Res; 1998; 18(6B):4635-9. PubMed ID: 9891532
[TBL] [Abstract][Full Text] [Related]
20. The relationship between serum tumor-associated trypsin inhibitor levels and clinicopathological parameters in patients with gastric cancer.
Kemik O; Kemik A; Sümer A; Almali N; Gurluler E; Gures N; Purisa S; Adas G; Dogan Y; Tuzun S
Eur Rev Med Pharmacol Sci; 2013 Nov; 17(21):2923-8. PubMed ID: 24254562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]